Sanofi, GlaxoSmithKline reach $2.1 billion deal with U.S. to supply vaccine doses

GSK on $2.1B vaccine supply deal with U.S.Подробнее

GSK Expects Vaccine Approval in First Half of 2021Подробнее

U.S. to pay Sanofi, GSK $2.1 bln for vaccinesПодробнее

Sanofi, GSK launch trial for COVID-19 vaccineПодробнее

Drug giants GSK and Sanofi to supply 60-M doses of coronavirus vaccines in the UKПодробнее

Sanofi, GSK say Covid-19 vaccine won't be ready until late 2021Подробнее

GSK and Sanofi joining forces to develop a vaccine for COVID-19Подробнее

Sanofi halts development of its Covid mRNA vaccineПодробнее

Sanofi, Glaxosmithkline to launch COVID-19 vaccine clinical trialПодробнее

Covid vaccine by Sanofi-GSK delayed after disappointing results in older patientsПодробнее

Glaxo Joins Forces With Sanofi to Develop Coronavirus VaccineПодробнее

Sanofi and GSK to join forces in vaccine collaboration to fight COVID-19Подробнее

Sanofi: Our vaccine could serve as an excellent booster shotПодробнее

Sanofi lifts earnings view, GSK holds forecastПодробнее

Novavax signs $1.2 billion vaccine deal with Sanofi #shortsПодробнее

Sanofi and GSK see positive interim results for their Covid vaccine in trialsПодробнее

Why GSK/Sanofi, Merck And Australian Vaccines Didn't Make The Cut | CRUXПодробнее

Sanofi to help produce doses of Pfizer-BioNTech Covid vaccineПодробнее

Sanofi Has Two Covid Vaccines in Clinical TrialsПодробнее